Codexis Inc (OQ:CDXS)

Business Focus: Biotechnology & Medical Research

Apr 18, 2024 04:05 pm ET
Codexis to Report First Quarter 2024 Financial Results on May 2
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the first quarter of 2024 on Thursday, May 2, 2024, following the close of market. Codexis management will host a...
Apr 11, 2024 07:05 am ET
Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the appointment of Carole Cobb, MBA, to the Company’s Strategic Advisory Board (SAB). Ms. Cobb is the former Chief Operating Officer at GreenLight Biosciences, a...
Feb 28, 2024 04:05 pm ET
Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced financial results for the fourth quarter and fiscal year ended December 31, 2023, and provided a business update. “We are thrilled with how we closed out 2023, and...
Feb 26, 2024 04:05 pm ET
Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an agreement with Roche for an exclusive, global license for the Company’s newly engineered double-stranded DNA (dsDNA) ligase for...
Feb 26, 2024 08:05 am ET
Codexis to Participate in TD Cowen 44th Annual Health Care Conference
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the TD Cowen 44th Annual Health Care Conference, being held March 4-6, 2024, in Boston, Massachusetts. Management will participate in a...
Feb 20, 2024 08:05 am ET
Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to the Company’s Strategic Advisory Board (SAB), joining John Maraganore, PhD, the founder and former...
Feb 14, 2024 04:05 pm ET
Codexis to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the fourth quarter and fiscal year 2023 on Wednesday, February 28, 2024, following the close of market. Codexis...
Feb 13, 2024 04:05 pm ET
Codexis Secures $40 Million in Strategic Financing Deal with Innovatus Capital Partners to Further Strengthen Cash Position Ahead of Key Milestones
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into a loan facility agreement with an affiliate of Innovatus Capital Partners, LLC (Innovatus) for up to $40 million, including $30 million upfront...
Feb 01, 2024 04:05 pm ET
seqWell and Codexis to Unveil Engineered Transposase Enzyme for Genomics Applications at AGBT General Meeting
seqWell, a global provider of genomic library workflow solutions, and Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the creation of an engineered high-performance transposase enzyme designed to drive superior...
Dec 27, 2023 08:30 am ET
Codexis Announces Purchase Agreement with Nestlé Health Science for CDX-7108
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into a purchase agreement with Nestlé Health Science, a globally recognized leader in the field of nutritional science, for CDX-7108, an...
Dec 13, 2023 04:06 pm ET
Codexis and Aldevron Enter Exclusive Licensing Agreement for Codex® HiCap RNA Polymerase
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an agreement with Aldevron, a global leader in the custom development and manufacture of plasmid DNA, RNA and proteins for the biotech industry,...
Dec 13, 2023 04:05 pm ET
Codexis Announces Achievement of Gram-scale Synthesis with its ECO Synthesis™ Platform
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has achieved gram-scale synthesis with its Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis™ technology. This critical technical milestone demonstrates the...
Dec 11, 2023 07:05 am ET
Codexis KOL Event Highlights Significant Need for an Enzymatic Route of Synthesis in RNAi Therapeutics Manufacturing
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, hosted a virtual Key Opinion Leader (KOL) event on Friday, December 8, 2023, to discuss the growth of RNA interference (RNAi) therapeutics as a modality, the manufacturing...
Nov 28, 2023 04:05 pm ET
Codexis to Host Virtual KOL Event on its ECO Synthesis™ Platform and the Future of RNAi Therapeutics Manufacturing on December 8, 2023
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it will host a virtual key opinion leader (KOL) event focused on its Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis™ platform and the broader RNA interference...
Nov 14, 2023 04:05 pm ET
Codexis to Participate in 35th Annual Piper Sandler Healthcare Conference
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the 35th Annual Piper Sandler Healthcare Conference, being held November 28-30, 2023, in New York, New York. Management will...
Nov 03, 2023 12:14 am ET
INVESTOR ALERT: Abbott Cooper PLLC Announces Investigation into Codexis, Inc.; Urges Codexis Stockholders to Contact Abbott Cooper Regarding Their Legal Rights
Abbott Cooper PLLC is investigating Codexis, Inc. (Nasdaq: CDXS) (“Codexis” or the “Company”) on behalf of the Company’s investors. The investigation seeks to determine whether Codexis’ board of directors (the “Board”) has violated its...
Nov 02, 2023 04:05 pm ET
Codexis Reports Third Quarter 2023 Financial Results
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced financial results for the third quarter ended September 30, 2023, and provided a business update. “Over the past quarter, we have continued to deliver on our plan...
Oct 31, 2023 04:05 pm ET
Codexis to Participate in Upcoming Healthcare Conferences
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that management will participate in four upcoming investor conferences. The Jefferies London Healthcare Conference (London, UK)   Tuesday, November 14, 2023, at...
Oct 27, 2023 03:35 pm ET
Codexis to Present Update on ECO Synthesis™ Platform at TIDES Europe
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced a presentation highlighting the role of an enzymatic approach to support RNA-based therapeutics manufacturing at the TIDES Europe annual meeting taking place in...
Oct 26, 2023 04:05 pm ET
Codexis to Present Update on ECO Synthesis™ Platform at TIDES Europe
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced a presentation highlighting the role of an enzymatic approach to support RNA-based therapeutics manufacturing at the TIDES Europe annual meeting taking place in...
Oct 19, 2023 04:05 pm ET
Codexis to Report Third Quarter 2023 Financial Results on November 2
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the third quarter of 2023 on Thursday, November 2, 2023, following the close of market. Codexis management will host a...
Sep 29, 2023 07:05 am ET
Codexis CEO Stephen Dilly Wins Prestigious 2023 Bloom Burton Award
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced President and Chief Executive Officer Stephen Dilly, MBBS, PhD, has been named the winner of the prestigious 2023 Bloom Burton Award. Dr. Dilly was recognized for...
Sep 18, 2023 04:05 pm ET
Codexis CEO Stephen Dilly Named as Finalist of 2023 Bloom Burton Award
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced Stephen Dilly, MBBS, PhD, President and Chief Executive Officer of Codexis, has been named a finalist for the prestigious 2023 Bloom Burton Award. Bestowed annually...
Sep 12, 2023 04:05 pm ET
Codexis to Participate in Cantor Global Healthcare Conference
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the Cantor Global Healthcare Conference, being held September 26-28, 2023, in New York, New York. Management will participate in a fireside...
Sep 07, 2023 04:05 pm ET
Codexis Announces Agreement for Assignment and Assumption of San Carlos Facility Lease
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company has executed an Assignment and Assumption of Lease for its San Carlos, California location. As a result of consolidating operations to its headquarters...
Aug 03, 2023 04:05 pm ET
Codexis Reports Second Quarter 2023 Financial Results
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced financial results for the second quarter ended June 30, 2023, and provided a business update. “We recently implemented pivotal changes as we...
Jul 31, 2023 04:05 pm ET
Codexis Documentary Showcases its Specialized Capabilities Engineering High Performance Enzymes to Enable Delivery of Novel Therapeutics
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the launch of a new mini documentary as part of an ongoing campaign in support of World Health Day. The film showcases the Company’s recently unveiled...
Jul 20, 2023 04:05 pm ET
Codexis Announces Enhanced Strategic Focus and Extends Projected Cash Runway to Mid-2026
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that, in alignment with its previously announced strategy to focus resources on programs with the strongest probability of creating significant value in the...
Jun 09, 2023 04:05 pm ET
Codexis Announces New Employment Inducement Grants
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the approval of equity grants to four new employees as approved by the Compensation Committee of Codexis’s Board of Directors. The newly hired employees received...
May 24, 2023 04:05 pm ET
Codexis to Participate in Jefferies Healthcare Conference
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the Jefferies Healthcare Conference, being held June 7-9, 2023, in New York, New York. Management will participate in a fireside chat on...
May 10, 2023 04:05 pm ET
Codexis Unveils ECO Synthesis™ Platform for Large-Scale RNAi Therapeutics Production at TIDES USA
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the unveiling of its Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis™ technology, a proprietary new synthesis platform being developed for manufacturing RNA...
May 08, 2023 04:05 pm ET
Codexis Announces New Employment Inducement Grants
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the approval of equity grants to five new employees as approved by the Compensation Committee of Codexis’s Board of Directors. The newly hired employees received...
May 04, 2023 04:05 pm ET
Codexis Reports First Quarter 2023 Financial Results
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced financial results for the first quarter ended March 31, 2023, and provided a business update. “We had a productive first quarter as we continued to execute our...
Apr 20, 2023 04:05 pm ET
Codexis to Report First Quarter 2023 Financial Results on May 4
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the first quarter of 2023 on Thursday, May 4, 2023, following the close of market. The Company will not be conducting...
Apr 19, 2023 04:05 pm ET
Codexis Announces RNA Therapeutics Manufacturing Workshop at TIDES USA
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it will host a pre-conference workshop highlighting the role of an enzymatic approach to support RNA-based therapeutics manufacturing at the TIDES USA annual...
Apr 06, 2023 04:05 pm ET
Codexis Announces New Employment Inducement Grants
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the approval of equity grants to two new employees as approved by the Compensation Committee of Codexis’s Board of Directors. The newly hired employees received...
Apr 04, 2023 04:05 pm ET
Codexis Announces Decision of Patrick Yang, PhD, Not to Seek Re-Election to Board of Directors
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that Patrick Yang, PhD, will not seek re-election to the Codexis Board of Directors. Dr. Yang joined the Board in 2014 and served as the Chair of the Nominating and...
Mar 09, 2023 04:05 pm ET
Codexis Announces New Employment Inducement Grants
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the approval of equity grants to two new employees as approved by the Compensation Committee of Codexis’s Board of Directors. The newly hired employees received...
Feb 27, 2023 04:05 pm ET
Codexis to Participate in Cowen 43rd Annual Health Care Conference
Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that management will participate in both a panel discussion and a fireside chat at the Cowen 43rd Annual Health Care Conference, being held March 6-8, 2023, in...
Feb 23, 2023 04:06 pm ET
Codexis Reports Fourth Quarter and Fiscal Year 2022 Financial Results
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced financial results for the fourth quarter and fiscal year ended December 31, 2022 and provided a business update. “2022 was an important year for Codexis as we...
Feb 23, 2023 04:05 pm ET
Codexis and Nestlé Health Science Announce Interim Results from Phase 1 Clinical Trial of CDX-7108 for Exocrine Pancreatic Insufficiency
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, and Nestlé Health Science, a leader in the science of nutrition, today announced interim results from a Phase 1 study to investigate the safety, tolerability, pharmacokinetics...
Feb 22, 2023 04:05 pm ET
Codexis Announces Several Key Presentations from its Gene Therapy Programs at 19th Annual WORLDSymposium™
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today highlights several key presentations from its gene therapy programs from 19th Annual WORLDSymposium™, taking place from February 22-26, 2023, in Orlando, Florida. Notably,...
Feb 15, 2023 04:05 pm ET
Codexis Announces New Employment Inducement Grants
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the grant of an inducement award to the Company’s recently appointed Chief Financial Officer, Sri Ryali. As previously announced, Mr. Ryali joined the Company on...
Feb 09, 2023 04:05 pm ET
Codexis to Report Fourth Quarter and Fiscal Year 2022 Financial Results on February 23
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the fourth quarter and fiscal year 2022 on Thursday, February 23, 2023, following the close of market. Codexis...
Jan 23, 2023 04:05 pm ET
Codexis Announces Appointment of Sri Ryali as Chief Financial Officer
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the appointment of Sri Ryali as Chief Financial Officer effective immediately. Mr. Ryali brings 20 years of finance and commercial experience in life sciences to...
Dec 20, 2022 04:05 pm ET
Codexis Announces Appointment of H. Stewart Parker to Board of Directors
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the appointment of H. Stewart Parker to its Board of Directors. “Stewart’s deep expertise in gene therapy and demonstrated track record of executive leadership...
Nov 29, 2022 04:05 pm ET
Codexis Provides Update on Prioritized Corporate Strategy
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced an update on the Company’s ongoing plan to prioritize its time and resources on areas where the Company believes it has the strongest commercial opportunity and...
Nov 16, 2022 04:05 pm ET
Codexis to Participate in Piper Sandler 34th Annual Healthcare Conference
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference, being held on...
Nov 08, 2022 04:05 pm ET
Codexis to Participate in Upcoming Healthcare Conferences
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management will participate in three upcoming investor conferences. The Stephens Annual Investment Conference on...
Nov 03, 2022 04:05 pm ET
Codexis Reports Third Quarter 2022 Financial Results
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced financial results for the third quarter ended September 30, 2022 and provided a business update. “In the last few months,...
Nov 01, 2022 08:00 am ET
Codexis Announces Appointment of Margaret Fitzgerald as Chief Legal Officer and General Counsel
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the appointment of Margaret (“Meg”) Fitzgerald as Chief Legal Officer and General Counsel, effective immediately. In this...
Oct 20, 2022 04:05 pm ET
Codexis to Report Third Quarter 2022 Financial Results on November 3
Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that it will report its financial results for the third quarter of 2022 on Thursday, November 3, 2022, following the close...
Oct 03, 2022 08:00 am ET
Codexis Announces Appointment of Kevin Norrett as Chief Operating Officer
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the appointment of Kevin Norrett as Chief Operating Officer (COO), effective immediately. In this role, Mr. Norrett is...
Oct 03, 2022 08:00 am ET
Codexis Announces Appointment of Rahul Singhvi, Sc.D., to Board of Directors
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the appointment of Rahul Singhvi, Sc.D., to its Board of Directors. Dr. Singhvi is a biotechnology industry veteran with...
Sep 14, 2022 04:05 pm ET
Codexis’ 2022 Protein Engineering Forum Showcases Recent Industry Success and Emerging Innovations in the Field
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the recent hosting of its in-person Protein Engineering Forum from September 12-13, 2022 in San Francisco, California....
Aug 04, 2022 04:05 pm ET
Codexis Reports Second Quarter 2022 Financial Results
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced financial results for the second quarter ended June 30, 2022 and provided a business update. “We continue to make solid...
Aug 02, 2022 04:05 pm ET
Codexis and Molecular Assemblies Announce Execution of Commercial License and Enzyme Supply Agreement for Optimized TdT Enzyme for Enzymatic DNA Synthesis
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, and Molecular Assemblies, Inc., a pioneer in the field of enzymatic DNA synthesis, today announced the execution of a Commercial License...
Jul 18, 2022 04:05 pm ET
Codexis Announces CEO Transition Effective August 9, 2022
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that its Board of Directors appointed Dr. Stephen Dilly, former CEO of Sierra Oncology, Inc. and current Codexis Board...
Jul 14, 2022 04:06 pm ET
Codexis Announces Agreement with Pfizer to Supply Enzyme for the Manufacture of PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets)
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that the Company has entered into an agreement with Pfizer for the supply of a proprietary high-performance enzyme used to...
Jul 14, 2022 04:05 pm ET
Codexis Announces Preliminary Second Quarter 2022 Results and Updates Guidance
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced preliminary revenue results for the second quarter ending June 30, 2022 and updated its revenue guidance for 2022. Codexis...
Jun 17, 2022 08:00 am ET
Codexis Announces the Publication of Research Demonstrating Proof of Concept for Chemoenzymatic Site-Selective Bioconjugation of Native Peptides
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announces the publication with Merck, known as MSD outside the United States and Canada, of a paper in the peer-reviewed journal...
May 25, 2022 04:05 pm ET
Codexis to Participate in Upcoming Healthcare Conferences
Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management will participate in three upcoming investor conferences. The 19th Annual Craig-Hallum Institutional...
May 17, 2022 04:05 pm ET
Codexis to Participate in Upcoming Healthcare Conferences
Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management will participate in two upcoming investor conferences. The UBS Global Healthcare Conference on May 23,...
May 16, 2022 08:00 am ET
Codexis Presents Pre-Clinical Data Highlighting Gene Therapy Programs at the ASGCT 25th Annual Meeting
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that three of its gene therapy programs are the subject of two poster presentations at the American Society of Gene and...
May 05, 2022 04:05 pm ET
Codexis Reports First Quarter 2022 Financial Results
Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced financial results for the first quarter ended March 31, 2022, and provided a business update. “I am very pleased with...
May 02, 2022 04:35 pm ET
Codexis to Present Data Highlighting Three Gene Therapy Programs at the ASGCT 25th Annual Meeting
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced two poster presentations highlighting three of the Company’s gene therapy programs using directed evolution to potentially...
Apr 21, 2022 04:05 pm ET
Codexis to Report First Quarter 2022 Financial Results on May 5
Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that it will report its financial results for the first quarter of 2022 on Thursday, May 5, 2022, following the close of...
Apr 21, 2022 08:00 am ET
Codexis and seqWell Announce Strategic Investment and Partnership Initiation
Codexis, Inc. (Nasdaq: CDXS) and seqWell, Inc. today announced the initiation of a strategic partnership and investment to accelerate the commercialization of seqWell’s genomics workflow solutions. Codexis, a leading enzyme engineering company...
Apr 21, 2022 07:57 am ET
Codexis and seqWell Announce Strategic Investment and Partnership Initiation
Codexis, Inc. (Nasdaq: CDXS) and seqWell, Inc. today announced the initiation of a strategic partnership and investment to accelerate the commercialization of seqWell’s genomics workflow solutions. Codexis, a leading enzyme engineering company enabling the promise of synthetic biology, and seqWell, a developer of transformative library preparation products for demanding genomics applications, plan to collaborate on using Codexis’ CodeEvolver® platform technology for enzyme optimization with seqWell’s growing portfolio of genomics workflow and library preparation products. As part of
Apr 12, 2022 08:00 am ET
Codexis and Molecular Assemblies Announce Results of First Collaboration on a Proprietary High Performing DNA Polymerase to Supercharge Fully Enzymatic DNA Synthesis
Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, and Molecular Assemblies, Inc., a pioneer in the field of enzymatic DNA synthesis, today announced an update on their partnership to...
Mar 01, 2022 04:05 pm ET
Codexis to Participate in the Cowen 42nd Annual Health Care Conference
Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management will participate in both a panel discussion and a fireside chat at the Cowen 42nd Annual Health Care...
Feb 24, 2022 04:05 pm ET
Codexis Reports Fourth Quarter and Fiscal Year 2021 Financial Results
Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced financial results for the fourth quarter and fiscal year ended December 31, 2021 and provided a business update. “2021 was...
Feb 10, 2022 04:05 pm ET
Codexis to Report Fourth Quarter and Fiscal Year 2021 Financial Results on February 24
Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that it will report its fourth quarter and fiscal year 2021 financial results on Thursday, February 24, 2022, following the...
Jan 24, 2022 08:00 am ET
Codexis Announces FDA Orphan Drug and Rare Pediatric Disease Designations for CDX 6512 for the Treatment of Homocystinuria
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation (ODD) for CDX-6512 for...
Jan 05, 2022 08:00 am ET
Codexis to Participate in the H.C. Wainwright Virtual BioConnect Conference
Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management will participate in a fireside chat at the H.C. Wainwright BioConnect 2022 Conference, being held virtually...
Dec 15, 2021 08:00 am ET
Codexis Launches Codex® HiTemp Reverse Transcriptase to Address Key Challenges in One-Step Assays for RNA Detection in PCR Testing, including COVID-19 Testing
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the launch of its Codex® HiTemp Reverse Transcriptase for use in one-step quantitative reverse transcription PCR...
Nov 22, 2021 08:00 am ET
Codexis Presents Pre-Clinical Data Highlighting its Programs in Homocystinuria and Maple Syrup Urine Disease at ICIEM 2021
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that two of the Company’s wholly owned biotherapeutic programs, CDX-6512 for the treatment of homocystinuria (HCU) and...
Nov 19, 2021 08:00 am ET
Codexis to Participate in Upcoming Virtual Healthcare Conferences
Codexis, inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management will participate in three upcoming virtual investment conferences. The Piper Sandler 33rd Annual Virtual...
Nov 15, 2021 08:00 am ET
Codexis Appoints Two New Senior Leaders for Human Resources and Corporate Development
Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the appointments of Karen Frechou-Armijo as Senior Vice President, Human Resources and Asli Aras, Ph.D., as Vice...
Nov 15, 2021 08:00 am ET
Codexis to Present Data Highlighting Two New Therapeutic Discovery Programs at the 14th International Congress of Inborn Errors of Metabolism 2021
Codexis, inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced two oral presentations highlighting its therapeutic discovery programs to develop potential treatments for homocystinuria...
Nov 09, 2021 04:05 pm ET
Codexis to Participate in Upcoming Virtual Healthcare Conferences
Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management will participate in three upcoming virtual investment conferences. The 12th Annual Craig-Hallum Alpha...
Nov 05, 2021 08:30 am ET
Thinking about buying stock in Assertio, Rewalk Robotics, Ontrak, Bigcommerce, or Codexis?
NEW YORK, Nov. 5, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ASRT, RWLK, OTRK, BIGC, and CDXS.
Nov 04, 2021 04:05 pm ET
Codexis Reports Third Quarter 2021 Financial Results
Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced financial results for the third quarter ended September 30, 2021 and provided a business update. “Codexis delivered...
Nov 04, 2021 08:00 am ET
The SynBio Innovation Accelerator, a Collaboration between Codexis and Casdin Capital, Enables $10 million Investment in Molecular Assemblies, Inc.
Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, and Casdin Capital, a leading life science investor, today announced a combined $10 million investment enabled by their SynBio Innovation...
Nov 03, 2021 04:05 pm ET
Codexis and Nestlé Health Science Initiate a Phase 1 Clinical Trial of CDX-7108 for Exocrine Pancreatic Insufficiency
Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company and developer of novel biotherapeutics, and Nestlé Health Science, a globally recognized leader in the field of nutritional science, announced today the dosing of the first subject...
Oct 21, 2021 04:05 pm ET
Codexis to Report Third Quarter 2021 Financial Results on November 4
Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that it will report its financial results for the third quarter of 2021 on Thursday, November 4, 2021, following the close...
Oct 18, 2021 08:00 am ET
Codexis, Almelo and RC2 Announce a Tri-Party Collaboration for the Enzymatic Production of Low Cost Sitagliptin API for the Generic Market, Including a License to Codexis Enzyme Technology in India
Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced a tri-party collaboration agreement with Almelo Private, Ltd., an Indian producer of active pharmaceutical ingredients (APIs),...
Sep 09, 2021 04:05 pm ET
Codexis and Merck Amend and Extend Supply Agreement for Enzyme Used in Manufacture of Sitagliptin
Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced the amendment and extension of its agreement with Merck, known as MSD outside the United States and Canada, to license and...
Sep 07, 2021 04:05 pm ET
Codexis to Participate in Upcoming Virtual Healthcare Conferences
Codexis, inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management will participate in two upcoming virtual investment conferences. The H.C. Wainwright 23rd Annual Global...
Aug 25, 2021 04:05 pm ET
Codexis Confirms Receipt of Follow-on Orders for Proprietary Enzyme Product from Undisclosed Global Pharmaceutical Company
Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced the Company received new purchase orders with an aggregate total value of approximately $15 million for the 2021 supply of a...
Aug 05, 2021 04:05 pm ET
Codexis Reports Second Quarter 2021 Financial Results
Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced financial results for the second quarter ended June 30, 2021 and provided a business update. “Codexis had an...
Aug 02, 2021 08:00 am ET
Codexis and Kalsec Announce Expanded Collaboration for Supply of Novel Enzyme to Sustainably Produce Natural Clean-Label Beverage Ingredient
Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, and Kalsec, Inc., a leading global producer of natural spice and herb extracts, colors, food protection and hop extracts for the food and...
Jul 26, 2021 04:05 pm ET
Codexis and Kalsec Announce Expanded Collaboration for Supply of Novel Enzyme to Sustainably Produce Natural Clean-Label Beverage Ingredient
Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, and Kalsec, Inc., a leading global producer of natural spice and herb extracts, colors, food protection and hop extracts for the food and...
Jul 22, 2021 04:05 pm ET
Codexis to Report Second Quarter 2021 Financial Results on August 5
Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that it will report its financial results for the second quarter of 2021 on Thursday, August 5, 2021, following the close...
Jul 14, 2021 04:05 pm ET
Codexis Announces Completion of CodeEvolver® License Technology Transfer with Global Pharmaceutical Leader
Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced the completion of the CodeEvolver® platform technology transfer with Novartis Pharma AG (“Novartis”) today. In May 2019, the two...
Jul 07, 2021 04:05 pm ET
Codexis Earns Milestone Payment from GlaxoSmithKline
Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced it earned a significant milestone payment related to the licensing of its proprietary CodeEvolver® protein engineering platform...
Jun 17, 2021 04:44 pm ET
Codexis Raises 2021 Guidance Following Receipt of Significant New Order for a Proprietary Enzyme Product
Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, is raising its guidance for 2021, following the receipt of a binding purchase order for up to $13.9 million of a proprietary high...
Jun 10, 2021 07:00 am ET
Codexis and Takeda Expand Strategic Collaboration and License Agreement to Discover Additional Gene Therapy for a Fourth Rare Genetic Disorder
Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, today announced the expansion of its strategic collaboration and license agreement with Takeda Pharmaceutical Company Limited (“Takeda”) for the research...
May 25, 2021 04:05 pm ET
Codexis to Participate in Upcoming Virtual Healthcare Conferences
Codexis, inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that management will participate in three upcoming virtual investment conferences. The Jefferies Virtual Healthcare Conference – June 1, 2021 at 4:30 p.m. ET a...
May 17, 2021 04:05 pm ET
Codexis to Participate in Upcoming Virtual Healthcare Conferences
Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that management will participate in three upcoming virtual investment conferences. The UBS Global Healthcare Virtual Conference – May 24, 2021 at 11:00 a.m. ET,...
May 06, 2021 04:05 pm ET
Codexis Reports First Quarter 2021 Financial Results
Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced financial results for the first quarter ended March 31, 2021 and provided a business update. “Codexis’ growth drivers are...
Apr 22, 2021 04:05 pm ET
Codexis to Report First Quarter 2021 Financial Results on May 6
Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the first quarter of 2021 on Thursday, May 6, 2021, following the close of market. Codexis management will host a...
Feb 25, 2021 04:05 pm ET
Codexis Reports Fourth Quarter and Fiscal Year 2020 Financial Results
Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced financial results for the fourth quarter and fiscal year ended December 31, 2020 and provided a business update. “Codexis delivered strong results in 2020, despite...
Feb 18, 2021 04:05 pm ET
Codexis to Present at Upcoming Virtual Healthcare Conferences
Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that management will present at three upcoming virtual investment conferences. The SVB Leerink 10th Annual Global Healthcare Conference – February 26, 2021 at 1:40...
Feb 11, 2021 04:05 pm ET
Codexis to Report Fourth Quarter and Full Year 2020 Results on February 25
Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that it will report fourth quarter and full year 2020 financial results on Thursday, February 25, 2021, following the close of market. Codexis management will host a...
Feb 09, 2021 04:05 pm ET
Codexis Announces Expansion to New Facility to Accommodate Next Stage of Growth
Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, announced today it will be expanding its operations into a new 36,000 square foot facility in San Carlos, CA under a ten year lease. This facility will provide space for additional...
Feb 03, 2021 04:05 pm ET
Codexis Appoints Dr. Esther Martinborough to its Board of Directors
Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced the appointment of Esther Martinborough, Ph.D., to its board of directors, expanding its membership to ten directors. Dr. Martinborough has over two decades of drug...
Jan 13, 2021 07:00 am ET
Codexis Introduces Improved Enzymes to Further Enhance Tate & Lyle's Stevia and Allulose Production
Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company and developer of high-performance enzymes, and Tate & Lyle (LSE: TATE.L), a leading global provider of food ingredients and solutions, have extended and deepened their relationship...
Jan 05, 2021 07:00 am ET
Codexis to Participate in the H.C. Wainwright Virtual BioConnect Conference
Codexis, Inc. (Nasdaq:CDXS), a leading protein engineering company, today announced that John Nicols, the Company’s President and Chief Executive officer, will participate in a fireside chat presentation at the H.C. Wainwright BioConnect 2021...
Dec 02, 2020 11:10 pm ET
Codexis Announces Pricing of Public Offering of Common Stock
Codexis, Inc. (Nasdaq:CDXS), a leading protein engineering company, today announced the pricing of an underwritten public offering of 4,285,715 shares of its common stock at a public offering price of $17.50 per share. Net proceeds to Codexis from...
Dec 02, 2020 04:24 pm ET
Codexis Announces Proposed Public Offering of Common Stock
Codexis, Inc. (Nasdaq:CDXS), a leading protein engineering company, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering will be offered by Codexis. In...
Nov 24, 2020 05:01 pm ET
Codexis and Casdin Capital Launch SynBio Innovation Accelerator
Codexis, Inc. (NASDAQ: CDXS), a leading Synthetic Biology company developing and supplying differentiated enzyme products for high value markets, in collaboration with leading life science investor Casdin Capital, announce the launch of SynBio...
Nov 09, 2020 07:00 am ET
Codexis to Participate at Three Virtual Investment Conferences in November
Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that management will participate at three upcoming virtual investment conferences: Stifel Healthcare Conference on Monday, November 16, 2020 with presentation at 3:20...
Nov 05, 2020 04:05 pm ET
Codexis Reports Third Quarter 2020 Financial Results
Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces financial results for the three and nine months ended September 30, 2020 and provides a business update.  “We are reporting another quarter of exceptional financial...
Oct 29, 2020 07:00 am ET
Codexis to Hold Third Quarter 2020 Conference Call on November 5
Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that it will report third quarter 2020 financial results after market close on Thursday, November 5, 2020. Codexis management will hold an investment community...
Sep 08, 2020 07:00 am ET
Codexis to Present at Two Virtual Investment Conferences in September
Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that management will present at two upcoming virtual investment conferences: H.C. Wainwright 22nd Annual Global Investment Conference on Monday, September 14, 2020 at...
Aug 06, 2020 04:05 pm ET
Codexis Reports Second Quarter 2020 Financial Results
Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces financial results for the three and six months ended June 30, 2020 and provides a business update.  Management will hold a conference call today beginning at 4:30 p.m....
Aug 06, 2020 07:00 am ET
Codexis Adds Dr. Jennifer L. Aaker to its Board of Directors
Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company and developer of high-performance enzymes, announced the appointment of Jennifer L. Aaker, Ph.D. to its board of directors, expanding membership to nine directors. Dr. Aaker is the...
Jun 23, 2020 07:00 am ET
Codexis and Molecular Assemblies Partner to Transform the Field of DNA Synthesis
Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company and developer of high-performance enzymes, and Molecular Assemblies, Inc., a pioneer in the field of enzymatic DNA synthesis, announce a partnership to engineer enzymes to deliver...
Jun 16, 2020 04:05 pm ET
Codexis Announces the Election of New Directors at its Annual Meeting of Stockholders
Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company and developer of high-performance enzymes, announces the election of new independent directors, Alison Moore, Ph.D. and Stephen Dilly, MBBS, Ph.D. at the company’s 2020 Annual...
Jun 01, 2020 04:05 pm ET
Codexis and Alphazyme Partner to Offer Novel Enzymes to Life Science and Diagnostic Markets
Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company and developer of high-performance enzymes, and Alphazyme LLC, an emerging leader in the development and manufacture of nucleic acid metabolizing enzymes, announce a Co-Marketing &...
May 27, 2020 07:00 am ET
Codexis to Participate in Two Virtual Investment Conferences
Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that management will participate in two virtual investment conferences: 17th Annual Craig-Hallum Institutional Investor Conference being held in a one-on-one meeting...
May 11, 2020 07:00 am ET
Codexis to Present at the UBS Virtual Healthcare Conference
Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that management will present at the UBS Virtual Healthcare Conference on Monday, May 18 at 9:10 a.m. Eastern time (6:10 a.m. Pacific time).  A live webcast and replay of...
May 07, 2020 04:05 pm ET
Codexis Reports First Quarter 2020 Financial Results
Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces financial results for the three months ended March 31, 2020 and provides a business update. “We are pleased to report strong financial results with $14.7 million in...
May 06, 2020 04:05 pm ET
Codexis Achieves Technology Transfer Milestone with Global Pharmaceutical Leader
Codexis, Inc., a leading protein engineering company and developer of novel biotherapeutics, announces achievement of the Wave 2 milestone associated with the CodeEvolver® platform technology transfer and license agreement with Novartis Pharma AG...
May 05, 2020 07:00 am ET
Codexis Expands and Strengthens its Leadership Team with Two Executive Hires
Codexis, Inc., a leading protein engineering company and developer of novel biotherapeutics, announces the appointment of Stefan Lutz, Ph.D. as Senior Vice President, Research and Karl A. Schoene, Ph.D. as Senior Vice President, Development &...
Apr 30, 2020 07:00 am ET
Codexis to Hold First Quarter 2020 Conference Call on May 7
Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report first quarter 2020 financial results after market close on Thursday, May 7, 2020.  Codexis management will hold an investment community conference...
Mar 23, 2020 07:00 am ET
Codexis Signs Strategic Collaboration and License Agreement with Takeda to Advance Novel Gene Therapies for Rare Genetic Disorders
Codexis, Inc., a leading protein engineering company and developer of novel biotherapeutics, announces the signing of a strategic collaboration and license agreement with Takeda Pharmaceutical Company Limited (Takeda) for the research and...
Feb 27, 2020 04:05 pm ET
Codexis Reports 2019 Fourth Quarter and Full Year Financial Results
Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces financial results for the three and 12 months ended December 31, 2019, provides a business update and introduces 2020 financial guidance. “Strong fourth quarter...
Feb 25, 2020 07:00 am ET
Codexis to Present at Two Investment Conferences in March
Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that management will present at two upcoming investment conferences: Cowen and Company 40th Annual Health Care Conference on Tuesday, March 3 at 11:20 a.m. Eastern...
Feb 20, 2020 07:00 am ET
Codexis to Hold 2019 Fourth Quarter and Full Year Conference Call on February 27
Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report 2019 fourth quarter and full year financial results after market close on Thursday, February 27, 2020. Codexis management will hold an investment...
Jan 13, 2020 04:05 pm ET
Codexis Attends Opening Ceremony for Porton’s Fermentation Pilot Lab in Chongqing
Codexis, Inc. (NASDAQ: CDXS) today announced that it has attended the official opening of Porton Pharma Solutions Ltd.’s (SZSE: 300363) fermentation pilot laboratory located in Porton’s Changshou site, achieving another important milestone in the...
Jan 10, 2020 07:00 am ET
Codexis and Nestlé Health Science Sign Development Agreement to Advance Therapeutic Candidate towards Clinical Studies and Extend Strategic Collaboration Agreement
Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company and developer of novel biotherapeutics, and Nestlé Health Science, a globally recognized leader in the field of nutritional science, have signed an agreement to advance a lead...
Dec 23, 2019 07:00 am ET
Codexis Announces License Agreement with Roche for Enzyme Used in Next Generation Sequencing
Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces a license agreement to provide Roche with Codexis’ EvoT4TM DNA ligase high-performance molecular diagnostic enzyme. This enzyme was developed using Codexis’ proprietary...
Dec 05, 2019 04:05 pm ET
Codexis Announces the Publication with Merck of an Efficient Enzymatic Cascade Process for Synthesis of Investigational Anti-HIV Agent, Islatravir
Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces the publication with Merck, known as MSD outside the United States and Canada, of a paper in the prestigious peer-reviewed journal Science, detailing the development of...
Nov 05, 2019 04:05 pm ET
Codexis Reports Third Quarter 2019 Financial Results
Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces financial results for the three and nine months ended September 30, 2019 and provides a business update. “Our exceptional financial performance for the third quarter...
Nov 05, 2019 07:00 am ET
Codexis to Participate in Four Investment Conferences in November
Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that management will participate in four upcoming investment conferences: 10th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 12, 2019.  The...
Oct 29, 2019 07:00 am ET
Codexis to Hold Third Quarter 2019 Conference Call on November 5
Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report third quarter 2019 financial results after market close on Tuesday, November 5, 2019.  Codexis management will hold an investment community...
Oct 15, 2019 04:05 pm ET
Codexis’ Protein Engineering Forum Highlights Progress and Future Direction of the Field
Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, assembled approximately 150 top scientists in protein engineering to discuss recent progress and future direction in a forum held last week in Palo Alto, Calif. Speakers...
Sep 26, 2019 08:00 am ET
Codexis Spreading the Promise of Engineered Proteins at SynBioBeta Summit
Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, is contributing resources and expertise to communicate protein engineering’s vast potential at SynBioBeta’s Global Synthetic Biology Summit in San Francisco, Oct. 1–3. SynBioBeta is a prominent network of biological engineers, investors, innovators and entrepreneurs.
Sep 26, 2019 07:00 am ET
Codexis to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that management will present at the 2019 Cantor Fitzgerald Global Healthcare Conference on Friday, October 4 at 12:00 p.m. Eastern time (9:00 a.m. Pacific time). The...
Aug 06, 2019 04:06 pm ET
Codexis Reports Second Quarter 2019 Financial Results
Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces financial results for the three and six months ended June 30, 2019 and provides a business update. “Product revenue increased a very solid 68% over the prior-year...
Aug 06, 2019 04:04 pm ET
Codexis Names Ross Taylor Senior Vice President and Chief Financial Officer
Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces the appointment of Ross Taylor as Senior Vice President and Chief Financial Officer effective August 19, 2019. Mr. Taylor will be responsible for managing all aspects of...
Jul 30, 2019 07:00 am ET
Codexis to Hold Second Quarter 2019 Conference Call on August 6
Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report second quarter 2019 financial results after market close on Tuesday, August 6, 2019. Codexis management will hold an investment community conference...
Jun 20, 2019 07:00 am ET
Casdin Capital Invests $50 Million in Codexis to Accelerate Strategic Growth Initiatives
Codexis, Inc. (Nasdaq: CDXS), a leading synthetic biology company, announces that Casdin Capital, LLC, a New York City-based life science-focused investment firm and current stockholder of Codexis, has invested approximately $50 million in Codexis...
May 30, 2019 07:00 am ET
Codexis to Present at the Jefferies 2019 Global Healthcare Conference
Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that management will present at the Jefferies 2019 Global Healthcare Conference on Thursday, June 6 at 2:30 p.m. Eastern time (11:30 a.m. Pacific time). The conference...
May 15, 2019 09:00 am ET
Codexis Announces CodeEvolver® Technology Transfer and License Agreement with Global Pharmaceutical Leader
Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces the signing of a CodeEvolver® platform agreement with Novartis. Under the terms of the agreement, Codexis has granted a non-exclusive license to its proprietary...
May 14, 2019 04:05 pm ET
Codexis to Participate at Three Investment Conferences in May
Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that management will participate in three upcoming investment conferences: UBS Global Healthcare Conference on May 21 at 8:00 a.m. Eastern time at the Grand Hyatt in...
May 06, 2019 04:06 pm ET
Codexis Reports First Quarter 2019 Financial Results
Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces financial results for the three months ended March 31, 2019 and provides a business update. “The start to 2019 has been exceptionally productive for Codexis,...
Apr 30, 2019 07:00 am ET
Codexis Signs Multi-Year Enzyme Supply and Licensing Agreement with Tate & Lyle for the Manufacture of TASTEVA® M Stevia Sweetener
Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces the signing of a multi-year agreement with Tate & Lyle, a global provider of food ingredients and solutions, for the supply and licensing of novel Codexis performance...
Apr 29, 2019 07:00 am ET
Codexis to Hold First Quarter 2019 Conference Call on May 6
Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report first quarter 2019 financial results after market close on Monday, May 6, 2019. Codexis management will hold an investment community conference call...
Apr 05, 2019 04:05 pm ET
Codexis Senior Vice President of R&D Dr. Jim Lalonde Announces Plan to Resign
Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that Jim Lalonde, Ph.D., Senior Vice President of Research and Development, will resign effective May 31, 2019 to pursue other interests. “Jim has played an integral...
Mar 05, 2019 07:00 am ET
Codexis to Participate in Two Investment Conferences in March
Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that management will participate in two upcoming investment conferences: Cowen and Company 39th Annual Health Care Conference on Tuesday, March 12 at 10:00 a.m. Eastern...
Mar 01, 2019 07:45 am ET
Analysis: Positioning to Benefit within Synchrony Financial, KKR & Co., Life Storage, Unum Group, Codexis, and Finisar — Research Highlights Growth, Revenue, and Consolidated Results
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Synchrony Financial (NYSE:SYF), KKR & Co. Inc. (NYSE:KKR), Life...
Feb 26, 2019 04:05 pm ET
Codexis Reports 2018 Fourth Quarter and Full Year Financial Results
Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces financial results for the three and 12 months ended December 31, 2018, provides a business update and introduces 2019 financial guidance. “We closed a highly...
Feb 25, 2019 07:00 am ET
Codexis Names Laurie Heilmann Senior Vice President of Business Development and Marketing
Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces the appointment of Laurie Heilmann to Senior Vice President of Business Development and Marketing. Heilmann brings to Codexis more than 30 years of leadership experience...
Feb 19, 2019 07:00 am ET
Codexis to Hold 2018 Fourth Quarter and Full Year Conference Call on February 26
Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report 2018 fourth quarter and full year financial results after market close on Tuesday, February 26, 2019. Codexis management will hold an investment...
Feb 14, 2019 07:00 am ET
Codexis Announces Nestlé Health Science Exercises Option for Exclusive Global License to CDX-6114 for the Management of Phenylketonuria
Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that Nestlé Health Science has exercised its option to obtain an exclusive license for the global development and commercialization of Codexis’ novel, orally delivered...
Feb 06, 2019 07:00 am ET
Codexis Announces Enzyme Supply Agreement with KYORIN Pharmaceutical for Overactive Bladder Drug Sold in Japan
Codexis, Inc. (NASDAQ: CDXS) announces a multi-year, exclusive supply agreement with KYORIN Pharmaceutical Co., Ltd. for the supply of a proprietary enzyme to be used in the manufacture of vibegron, an active ingredient in Beova® Tablets, a novel,...
Feb 04, 2019 04:05 pm ET
Codexis Secures Multi-Year Technology Upgrade Package for its CodeEvolver Protein Engineering Platform License with Merck
Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces the signing of a new agreement with Merck, through a subsidiary. Under the terms of the agreement, Codexis will install certain CodeEvolver® protein engineering...
Nov 28, 2018 08:45 am ET
Report: Developing Opportunities within Costco Wholesale, Pepsico, Northern Oil and Gas, Codexis, Sangamo Therapeutics, and BRF S.A. — Future Expectations, Projections Moving into 2018
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Costco Wholesale Corporation (NASDAQ:COST), Pepsico, Inc. (NASDAQ:PEP),...
Nov 08, 2018 04:05 pm ET
Codexis Reports Third Quarter 2018 Financial Results
Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces financial results for the three and nine months ended September 30, 2018 and provides a business update. “We are pleased to report another quarter of outstanding...
Nov 08, 2018 07:00 am ET
Codexis Announces Results of Phase 1a Clinical Trial with CDX-6114
Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces top-line results from its Phase 1a single ascending-dose study in healthy volunteers with CDX-6114, its orally administered enzyme candidate for the potential treatment...
Nov 07, 2018 04:05 pm ET
Codexis to Present at Two Investment Conferences in November
Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that management will present at two upcoming investment conferences: 9th Annual Craig-Hallum Alpha Select Conference on Thursday, November 15, 2018. The conference is...
Nov 01, 2018 07:00 am ET
Codexis to Hold Third Quarter 2018 Conference Call on November 8
Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report third quarter 2018 financial results after market close on Thursday, November 8, 2018. Codexis management will hold an investment community...
Oct 17, 2018 07:20 am ET
Investor Expectations to Drive Momentum within Arsanis, Dynavax Technologies, Puma Biotechnology, Opko Health, Adaptimmune Therapeutics, and Codexis — Discovering Underlying Factors of Influence
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Arsanis, Inc. (NASDAQ:ASNS), Dynavax Technologies Corporation...
Oct 01, 2018 07:00 am ET
Codexis Appoints Claus Ladefoged to Global Enzyme Business Development Role
Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces the appointment of Claus Ladefoged as Director, Enzyme Business Development.  Ladefoged has extensive experience in successfully building relationships and developing...
Aug 29, 2018 07:00 am ET
Codexis to Present at Three Investment Conferences in September
Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that management will present at three upcoming investment conferences: H.C. Wainwright 20th Annual Global investment Conference on Wednesday, September 5, 2018 at 2:35...
Aug 20, 2018 08:10 am ET
Report: Exploring Fundamental Drivers Behind Codexis, Kornit Digital, NewLink Genetics, NCS Multistage, Mountain Province Diamonds, and CSS Industries — New Horizons, Emerging Trends, and Upcoming Dev
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Codexis, Inc. (NASDAQ:CDXS), Kornit Digital Ltd. (NASDAQ:KRNT), NewLink...
Aug 08, 2018 04:05 pm ET
Codexis Reports Second Quarter 2018 Financial Results
Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces financial results for the three and six months ended June 30, 2018 and provides a business update. “I’m proud of our outstanding financial and operating performance...
Aug 01, 2018 07:00 am ET
Codexis to Hold Second Quarter 2018 Conference Call on August 8
Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report second quarter 2018 financial results after market close on Wednesday, August 8, 2018. Codexis management will hold an investment community...
Jul 11, 2018 07:00 am ET
Codexis Appoints Dr. Hicham Alaoui, Veteran Drug Discoverer, as Vice President, Biotherapeutics Research & Development
Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces the appointment of Hicham Alaoui, Ph.D. to the newly created position of Vice President, Biotherapeutics Research Development. The appointment brings Dr. Alaoui’s...
Jul 09, 2018 08:00 am ET
Codexis Doses First Subjects in Phase 1a Trial of CDX-6114
Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that it has dosed the first subjects in a first-in-human Phase 1a dose-escalation trial with CDX-6114, its orally administered enzyme therapeutic being developed for the...
Jun 01, 2018 08:00 am ET
New Research Coverage Highlights WPP, Codexis, Natural Resource Partners LP, Mercer International, Booking, and SINOPEC Shangai Petrochemical — Consolidated Revenues, Company Growth, and Expectations
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of WPP PLC (NYSE:WPP), Codexis, Inc. (NASDAQ:CDXS), Natural Resource Partners...
May 29, 2018 07:00 am ET
Codexis to Present at Three Upcoming Investment Conferences
Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that management will present at three upcoming investment conferences: 15th Annual Craig-Hallum Institutional Investor Conference on Wednesday, May 30, at The Depot...
May 10, 2018 04:05 pm ET
Codexis Reports First Quarter 2018 Financial Results
Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces financial results for the three months ended March 31, 2018 and provides a business update. “We began the year with strong first quarter revenues of $14 million, a 76%...
May 03, 2018 07:00 am ET
Codexis to Hold First Quarter 2018 Conference Call on May 10
REDWOOD CITY, Calif., May 03, 2018 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that it will report first quarter 2018 financial results after market close on Thursday, May 10, 2018. Codexis management will...
Apr 23, 2018 06:00 am ET
Apr 09, 2018 08:10 am ET
New Research Coverage Highlights Alliance Resource Partners, MyoKardia, Pan American Silver, Stitch Fix, Codexis, and Chemical Financial — Consolidated Revenues, Company Growth, and Expectations for 2
NEW YORK, April 09, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Alliance Resource Partners, L.P. (NASDAQ:ARLP), MyoKardia,...
Apr 05, 2018 09:15 pm ET
Codexis Announces Pricing of Public Offering of Common Stock
REDWOOD CITY, Calif., April 05, 2018 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading protein engineering company, today announced the pricing of an underwritten public offering of 3,750,000 shares of its common stock at a public offering price of...
Apr 05, 2018 04:02 pm ET
Codexis Announces Proposed Public Offering of Common Stock
REDWOOD CITY, Calif., April 05, 2018 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading protein engineering company, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to...
Apr 05, 2018 07:00 am ET
Codexis to Present at H.C. Wainwright Global Life Sciences Conference in Monte Carlo, Monaco
REDWOOD CITY, Calif., April 05, 2018 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that management will present at the H.C. Wainwright Global Life Sciences Conference on Tuesday, April 10, 2018 at 9:50 a.m....
Mar 13, 2018 08:10 am ET
Detailed Research: Economic Perspectives on GRIDSUM HOLDING, Booking, POSCO, Codexis, Third Point Reinsurance, and Arch Capital Group — What Drives Growth in Today's Competitive Landscape
NEW YORK, March 13, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of GRIDSUM HOLDING (NASDAQ:GSUM), Booking Holdings Inc....
Mar 08, 2018 04:05 pm ET
Codexis Reports 2017 Fourth Quarter and Full Year Financial Results
 2017 revenues of $50 million include a 74% increase in product salesIntroduces 2018 financial guidance
Mar 01, 2018 07:00 am ET
Codexis to Hold 2017 Fourth Quarter and Full Year Conference Call on March 8
REDWOOD CITY, Calif., March 01, 2018 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that it will report fourth quarter and full year 2017 financial results after market close on Thursday, March 8, 2018....
Feb 15, 2018 07:00 am ET
Codexis Appoints Molecular Diagnostics Industry Veteran Shawn Clairmont to Lead High-Performance Enzymes Commercialization
REDWOOD CITY, Calif., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces the appointment of Shawn Clairmont to the newly created position of Senior Director, Molecular Diagnostics. Codexis is expanding into the...
Feb 12, 2018 07:00 am ET
Codexis to Present at the 25th International Molecular Medicine Tri-Conference
REDWOOD CITY, Calif., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that John Nicols, President & CEO, will discuss the development of an improved DNA ligase for the molecular diagnostics...
Nov 09, 2017 04:05 pm ET
Codexis Reports Financial Results for the Third Quarter of 2017
Product sales increase 71% over the prior year
Nov 09, 2017 07:00 am ET
Codexis to Present at Two Investment Conferences in November
REDWOOD CITY, Calif., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that management will present at two investment conferences in November:...
Nov 09, 2017 07:00 am ET
Codexis to Present at Two Investment Conferences in November
REDWOOD CITY, Calif., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that management will present at two investment conferences in November:
Nov 02, 2017 07:00 am ET
Codexis to Hold 2017 Third Quarter Conference Call on November 9
REDWOOD CITY, Calif, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that it will report third quarter 2017 financial results after market close on Thursday, November 9, 2017. Codexis management will...
Oct 12, 2017 08:00 am ET
Codexis and Nestlé Health Science Enter Into Healthcare-Focused Protein Engineering Platform Partnership
Includes an option for the global development of CDX-6114 for PKU, marking Codexis’ first partnership for an internally developed biotherapeutic product.  Codexis receives an upfront payment of $14 million and potential milestones and royalties depending on product success   In addition, the partnership adds strategic access to the CodeEvolver® platform for the discovery of additional enzyme therapies for other metabolic disorders requiring drug therapy, as well as novel enzymes for use in medical nutrition and consumer care products REDWOOD CITY, Calif, Oct. 12, 2017 (GLOBE NEWSWIRE) -- ...
Aug 31, 2017 07:00 am ET
Codexis to Present at Four Investment Conferences in September
REDWOOD CITY, Calif., Aug. 31, 2017 (GLOBE NEWSWIRE) --  Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that management will present at four investment conferences in September:...
Aug 09, 2017 04:05 pm ET
Codexis Reports Financial Results for the Second Quarter of 2017
Product sales more than doubled versus prior-year second quarter...
Mar 09, 2017 04:05 pm ET
Codexis Reports 2016 Fourth Quarter and Full Year Financial Results
Achieves 2016 total revenues and gross margin guidance, introduces 2017 financial guidance...
Dec 01, 2016 07:00 am ET
Codexis Names Pharmaceutical Industry Veteran Bernard J. Kelley Chairman of the Board
REDWOOD CITY, Calif., Dec. 01, 2016 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that Bernard J. Kelley has been named Chairman of the Board, effective November 29, 2016. Mr. Kelley has served as a Director of Codexis since April 2004.  He has succeeded former Board Chairman Thomas Baruch, who will continue as a Director and has been named Codexis Chairman Emeritus, an honorary title to recognize his contributions to the company....
Nov 10, 2016 07:00 am ET
Codexis to Present at the 7th Annual Craig-Hallum Alpha Select Conference
REDWOOD CITY, Calif., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that management will present at the 7th Annual Craig-Hallum Alpha Select Conference on Wednesday, November 16, at 11:20 a.m. Eastern time (8:20 a.m. Pacific time).  The conference is being held at the Sheraton Times Square Hotel in New York City....
Nov 08, 2016 04:05 pm ET
Codexis Reports Financial Results for the Third Quarter of 2016
Revenues of $14.9 million driven by core biocatalyst product sales increase of 123%and include $8.0 million milestone revenue from Merck...
Nov 01, 2016 07:00 am ET
Codexis to Hold 2016 Third Quarter Conference Call on November 8
REDWOOD CITY, Calif., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that it will report third quarter 2016 financial results after market close on Tuesday, November 8, 2016.  Codexis management will hold an investment community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss financial results and provide a company update. ...
Oct 17, 2016 07:00 am ET
Michael Aldridge Joins Codexis as Senior Vice President, Corporate & Strategic Development
REDWOOD CITY, Calif., Oct. 17, 2016 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that Michael Aldridge has joined the company as Senior Vice President, Corporate & Strategic Development.  In this new position, Mr. Aldridge will manage all aspects of Codexis’ growth initiatives, including leading the expansion of the global biocatalyst business, striking new CodeEvolver® platform licensing agreements and building momentum in the Company’s pipeline of therapeutic drug candidates.  He will report to John Nicols, President and Chief Exec...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.